Popular on Amzeal
- Human Resources Strategy Forum Celebrates 30 Years Empowering Leaders, Shaping the Next Generation of HR Innovators - 119
- Omnitronics Proud to Join NXDN Forum
- Legionnaire Awarded $3.19M AFWERX Contract to Develop Next Generation Air-refueling System
- Diana Partners With OpsVeda To Leverage AI-ML To Get Closer To Its Consumers
- Phishing Protection Industry Growth, Development and Forecast Report, 2030
- Allegiant Management Group Launches New Website Following Recent Rebranding
- E.G. Phillips Cinematic Single a Fiery Rebuke to Election Season Chaos Agents
- Ron Johnson Announced as the 39th Black Engineer of the Year
- Democracy at Work & The Left Forum Presents Seminar with Professor Richard D. Wolff based on "Understanding Capitalism"
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New Doctor of Behavioral Health Graduates
Similar on Amzeal
- Carl Resnick joins Flexible Plan Investments as vice president of national sales
- CCHR Wants Increased Consumer Awareness About "Prescriptions for Violence"
- ALLTRA SonicSwap Expands DeFi Opportunities with Weekly Listings and Global Partnerships
- ALL Mainnet Launches AUSDT Stablecoin onto the global arena
- The Giving Edge: Is Leveraging Outrageous Kindness the Missing Link for Corporate ROI?
- Cummings Graduate Institute for Behavioral Health Studies Announces New Book: Integrated Behavioral Health: Applying the Biodyne Mindset in Healthcare
- Smart Merchant Solution goes BLUU to strengthen its position in the Point of Sale (POS) Solutions and Payments Processing Sector
- Bug Busters Celebrates 40 Years in the Pest Control Industry
- Dr. Stephen Shainbart, PHD, Highlights 5 Reasons to Discuss Family Therapy and Couples Counseling in Buffalo, NY
- Restoration Specialists Celebrates a Successful 2024 and Strong Q4
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
Amzeal News/10572885
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - Amzeal -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on Amzeal News
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on Amzeal News
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on Amzeal News
- Nurturing Healthy Smiles Through Little Mouth Program
- Experience the Future of Digital Textbook with KITABOO at FBF 2024 and Win an iPad Daily!
- Integris Composites Displays New Military Armor at AUSA 2024
- Expert HVAC Upgrade Tips to Maximize Energy Efficiency
- Ledger Wallet: The Secure Crypto Storage Solution Every Investor Needs Today
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on Amzeal News
- ALLTRA SmartChain Partners with Kryptobox.io to Enhance Global Digital Asset Accessibility
- ALLTRA SonicSwap Expands DeFi Opportunities with Weekly Listings and Global Partnerships
- ALL Mainnet Launches AUSDT Stablecoin onto the global arena
- Alana Winns Steps Down as Editor-in-Chief and Chief Content Officer of Career Communications Group
- The Giving Edge: Is Leveraging Outrageous Kindness the Missing Link for Corporate ROI?
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on Amzeal News
- Invenio IT Partners with Vonahi Security to Offer Automated Network Penetration Testing for Enhanced Security
- National Minority Health Association and Cell-Ed Announce Upcoming Webinar: Empowering Caregivers Through Innovative Training Programs
- ASI Launches 2025 iMISĀ® Membership Benchmark Survey; Open Until October 31
- Cyber Safe Institute Hosts Landmark AI Quantum Cybersecurity Career Fair at NIST Cybersecurity Week
- Free 6-Month Premium Matrimonial Membership Now Available on IndoMarry.com
- NEMTAC Announces Public Comment Period for the NEMTAC 3001-202X Transportation Specialist Education Draft Standard
- Dr. Stephen Shainbart, PHD, Highlights 5 Reasons to Discuss Family Therapy and Couples Counseling in Buffalo, NY
- Restoration Specialists Celebrates a Successful 2024 and Strong Q4
- Purple Union C-Murder Supporting Angola Prisoners in Their Fight for Basic Human Rights Through Labor Strike
- Secure Life App Launches: A Revolutionary Health and Safety Platform for You and Your Loved Ones
- NetverseAI and NetaverseAI By Phinge Will Be The Safest and Only Verified AI In The World
- OpsVeda Is Now Available Through AWS Marketplace
- Circumference Group Acquires Majority Stake in Visionary Integration Professionals
- Tim O'Loughlin Appointed Chief Executive Officer of Vantiva and Co-opted as a Director of the Board
- TN Nursery Gears Up for Busy Fall Shipping Season with Nationwide Fast Shipping, Low Grower Prices, and Storewide Deals
- Energy Psychology Group Announces Conclusion of Strategic Alliance with Cosmic Media
- Jazz Artist Bob Holz Signs With SoVibe Entertainment Plus Album Review In September 2024 Issue Of Downbeat Magazine
- Develop Africa Partners with Sierra Leonean Painter Sahr Songu Mbriwa to Raise Funds for Education
- Composer Andrew Prahlow to Perform Award-Winning Outer Wilds Soundtrack on Oct 17th at Brooklyn's Music Hall of Williamsburg
- CostPredict Inc. Accepted for Participation in an Exclusive Tech Venture Accelerator Program